Kidney transplant drug dosing gets a closer look
NCT ID NCT01435291
First seen Apr 04, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This study looked at how the drug Advagraf (a type of tacrolimus) behaves in the body right after a kidney transplant and three months later. Researchers measured drug levels in 45 adult kidney transplant patients to find the best dose. The goal was to improve dosing methods, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHRU Tours Hôpital Bretonneau
Tours, France
-
CHU de Nice
Nice, 06200, France
-
CHU de Rangueil
Toulouse, France
-
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Conditions
Explore the condition pages connected to this study.